Bio-Techne Corporation — FY2015 Form 10-K Summary
Reporting period: The filing covers the fiscal year ended June 30, 2015, with comparative results for fiscal 2014 and 2013. This differs from the request metadata’s “2014 Q4.” Amounts below are U.S. dollars.
Business context
Bio-Techne develops, manufactures and sells biotechnology research and diagnostic products, clinical controls and calibrators, and protein-analysis instruments and consumables. Fiscal 2015 sales were 72.1% Biotechnology, 13.3% Clinical Controls and 14.6% Protein Platforms. The Protein Platforms segment was established following the ProteinSimple and CyVek acquisitions.
Financial performance and liquidity
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Net sales | $452.2 million | $357.8 million | +26% |
| Operating income | $147.0 million | $159.8 million | -8% |
| Net earnings | $107.7 million | $110.9 million | -3% |
| Diluted EPS | $2.89 | $3.00 | -4% |
| Operating cash flow | $139.4 million | $136.8 million | +2% |
| Capital expenditures | $19.9 million | $13.8 million | +$6.1 million |
- Reported gross margin declined to 67.9% from 70.3%; management’s adjusted gross margin, excluding acquired-inventory costs and intangible amortization, was 71.6% versus 73.5%.
- Operating margin was approximately 32.5%, versus 44.7% in FY2014. Higher acquisition-related operating expenses and amortization weighed on reported operating income.
- Cash and cash equivalents were $54.5 million and short-term available-for-sale investments were $56.4 million at June 30, 2015. The investment balance included Bio-Techne’s $52.3 million ChemoCentryx investment.
- Working capital was $208.5 million, down from $443.0 million. Long-term debt was $73.0 million; the company had a $150 million revolving facility, with potential capacity to increase it by a further $150 million subject to conditions.
- Cash used in investing activities was $426.5 million, including $420.1 million for acquisitions. Cash dividends paid were $47.1 million; the annual dividend declared per share was $1.27.
Material changes versus prior period
- Management attributed FY2015 sales growth to 25% acquisition contribution and 4% organic growth, partly offset by a 2% adverse currency effect. Organic growth was reported in Biotechnology and Clinical Controls.
- Biotechnology sales rose 8% to $325.9 million; excluding Novus sales and adverse currency effects, organic growth was 3%. Clinical Controls sales rose 6% to $60.4 million, with 5% organic growth and 1% from Bionostics. Protein Platforms contributed $66.2 million.
- Novus, ProteinSimple and CyVek were acquired during FY2015 for approximately $60 million, $300 million and $95 million, respectively, including contingent consideration for CyVek. Goodwill rose to $390.6 million from $151.5 million and net intangible assets to $292.8 million from $108.8 million.
- GAAP net earnings fell 3%, while management’s non-GAAP adjusted net earnings increased 1%, to $126.8 million from $125.3 million. The adjustment includes acquisition-related costs, acquired-inventory charges, intangible amortization and tax items, and removes an $8.3 million CyVek investment gain.
Outlook, risks and unusual items
- Management expected available funds, operating cash flow and the credit line to meet operating, capital, facility and dividend needs for at least the next 12 months. Planned FY2016 capital expenditures were approximately $20 million. The filing provides no specific revenue or earnings guidance.
- Management cited a strong U.S. bio-pharma market and significant Chinese life-science research funding as FY2015 growth drivers. It noted that acquisitions, product mix, foreign exchange and lower-priced product offerings could continue to affect margins.
- Key risks include dependence on research and government funding, competition and pricing pressure, acquisition integration and execution, foreign currency exposure, product innovation, regulatory compliance, intellectual property, manufacturing and supply continuity, cybersecurity, and implementation of a new ERP system.
- Euro translation reduced FY2015 sales by approximately $8.5 million versus FY2014. A hypothetical 10% U.S. dollar appreciation against the euro, pound and yuan was estimated to reduce translated earnings by $3.4 million.
- CyVek contingent consideration included up to $35 million tied to product revenue through 2017, plus a potential payment linked to 2020 revenue above $100 million. The company recorded $35.0 million for the first contingent payment at June 30, 2015.
- Cliniqa was acquired on July 8, 2015, after fiscal year-end. The filing reported no legal proceedings expected to have a material adverse effect. KPMG gave unqualified opinions on the financial statements and internal control; the internal-control assessment excluded certain acquired businesses representing 47.9% of assets and 18.7% of revenue.
Important facts for investors to verify
- How much of reported growth and future earnings depends on successful integration and performance of ProteinSimple, CyVek, Novus and the subsequent Cliniqa acquisition.
- The sustainability of organic growth and margins, given lower FY2015 adjusted gross margin, acquisition-related amortization and product-mix effects.
- Current debt drawn, covenant headroom, variable-rate exposure and the cash impact of CyVek contingent payments.
- The value and liquidity of the ChemoCentryx investment, including its valuation, market-price volatility and concentration within available-for-sale investments.
- Progress on ERP implementation and the extension of internal-control assessments to acquired businesses.